Literature DB >> 32038916

Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer.

Maria Jove1,2, Noelia Vilariño1,2, Ernest Nadal1,2.   

Abstract

Entities:  

Year:  2019        PMID： 32038916      PMCID： PMC6987359          DOI： 10.21037/tlcr.2019.06.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  13 in total

Review 1.  Immune regulation by glucocorticoids.

Authors:  Derek W Cain; John A Cidlowski
Journal:  Nat Rev Immunol       Date:  2017-02-13       Impact factor: 53.106

2.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  D Planchard; S Popat; K Kerr; S Novello; E F Smit; C Faivre-Finn; T S Mok; M Reck; P E Van Schil; M D Hellmann; S Peters
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Authors:  Kathryn C Arbour; Laura Mezquita; Niamh Long; Hira Rizvi; Edouard Auclin; Andy Ni; Gala Martínez-Bernal; Roberto Ferrara; W Victoria Lai; Lizza E L Hendriks; Joshua K Sabari; Caroline Caramella; Andrew J Plodkowski; Darragh Halpenny; Jamie E Chaft; David Planchard; Gregory J Riely; Benjamin Besse; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-08-20       Impact factor: 44.544

5.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

7.  A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index.

Authors:  B Colinet; W Jacot; D Bertrand; S Lacombe; M-C Bozonnat; J-P Daurès; J-L Pujol
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

8.  Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.

Authors:  Giovanni Fucà; Giulia Galli; Marta Poggi; Giuseppe Lo Russo; Claudia Proto; Martina Imbimbo; Roberto Ferrara; Nicoletta Zilembo; Monica Ganzinelli; Antonio Sica; Valter Torri; Mario Paolo Colombo; Claudio Vernieri; Andrea Balsari; Filippo de Braud; Marina Chiara Garassino; Diego Signorelli
Journal:  ESMO Open       Date:  2019-02-27

9.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

10.  Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.

Authors:  Amber J Giles; Marsha-Kay N D Hutchinson; Heather M Sonnemann; Jinkyu Jung; Peter E Fecci; Nivedita M Ratnam; Wei Zhang; Hua Song; Rolanda Bailey; Dionne Davis; Caitlin M Reid; Deric M Park; Mark R Gilbert
Journal:  J Immunother Cancer       Date:  2018-06-11       Impact factor: 13.751
View more
  5 in total

1.  Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.

Authors:  Jeong A Park; Linlin Wang; Nai-Kong V Cheung
Journal:  J Hematol Oncol       Date:  2021-09-08       Impact factor: 23.168

Review 2.  Effect of pretreatment with dexamethasone on the efficacy and immune-related adverse events of immunotherapy in first-line treatment for advanced non-small cell lung cancer: a network meta-analysis of randomized control trials.

Authors:  Yanwei Li; Feng He; Shuang Liu; Yu Zhang; Ling Li; Bin Wang; Lan Lan; Zhanyu Pan
Journal:  Am J Clin Exp Immunol       Date:  2021-12-15

3.  Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer.

Authors:  Naoya Nishioka; Tateaki Naito; Akifumi Notsu; Keita Mori; Hiroaki Kodama; Eriko Miyawaki; Taichi Miyawaki; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Koichi Takayama; Toshiaki Takahashi
Journal:  Cancer Med       Date:  2020-12-10       Impact factor: 4.452

Review 4.  Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).

Authors:  Wolfgang M Brueckl; Joachim H Ficker; Gloria Zeitler
Journal:  BMC Cancer       Date:  2020-12-03       Impact factor: 4.430

Review 5.  Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.

Authors:  Liansha Tang; Jialing Wang; Nan Lin; Yuwen Zhou; Wenbo He; Jiyan Liu; Xuelei Ma
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.